Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of oncology-focused biotech company Threshold Pharmaceuticals
So what: In February we were given statistically significant evidence that TH-302 -- a drug that works by targeting the hypoxic cells often found in solid tumors but rarely found in normal tissue -- in combination with Gemzar successfully extended survival rates to 5.5 months from 3.5 months with Gemzar treatment alone. Today's results added to that initial study demonstrating a 2.3 month survival improvement at the median, to 9.2 months from 6.9 months.
On the flip side, adding TH-302 with Gemzar as opposed to using Gemzar alone only reduced the relative risk of death by a not-so-significant 4.5%. Threshold also alluded that about one-third of its 214-patient mid-stage trial may have skewed the results in favor of TH-302. That one-third was switched from Gemzar alone to the combination therapy as soon as tumor progression was noticed.
Now what: Threshold is bound to be a fickle and highly volatile company with just one drug in its pipeline, TH-302. However, TH-302 is being tested in 11 different clinical trials at the moment, including in combination with Pfizer's
But Threshold won't have an easy go of things even if it gains FDA approval of TH-302 in combination with Gemzar. Both Peregrine Pharmaceuticials'
Craving more input? Start by adding Threshold Pharmaceuticals to your free and personalized Watchlist so you can keep up on the latest news with the company.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.